Psyence Group

The investment we secured from Cantheon Capital, LLC, a fund focussed on listed stocks with near term catalysts, will help fund our first clinical trial in Australia. The funding will go towards the design and conduct of our Phase IIb clinical trial, using a natural psilocybin drug candidate PEX010, in the palliative care setting.

We have partnered with iNGENu CRO to conduct the trial and believe that the funding will enable us to progress this trial as expeditiously as possible.

Psyence Group Announces Cantheon Capital Private Placement Psyence Group Announces Cantheon Capital Private Placement Vancouver, British Columbia, March 23, 2023 – Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce that it has en...

New year, new milestone for Psyence Group as we announce our partnership with iNGENū CRO. iNGENū has extensive experience in the psychedelic pharmaceutical drug development and clinical research industry.

iNGENū will be responsible for jointly designing our Phase IIb clinical trial, which will be conducted in Australia.

Australia’s highly supportive clinical research and regulatory environment has made it a key early research destination for Psyence and we are excited to kick 2023 off on this positive note.

Psyence Signs Letter of Intent with Australian CRO iNGENū Psyence Signs Letter of Intent with Australian CRO iNGENū Vancouver, British Columbia, January 09, 2023 – Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, today announced that it has signed ...

Our functional mushroom product, GOODMIND™, is now available for sale in the United Kingdom and Europe.

It has always been our intention to expand our formulas, together with our joint venture partner Goodleaf, beyond South Africa and we are delighted to have reached this significant milestone.

We have partnered with This Works to distribute and sell our products in these strategic markets. GOODMIND™ is available for sale in the UK and EU via www.thisworks.com and in South Africa www.foragoodmind.com.



https://psyence.com/2022/11/29/goodmind-available-for-sale-in-the-united-kingdom-and-europe-exclusive-distribution-agreement-concluded-with-this-works/

GOODMIND Available For Sale In The United Kingdom And Europe - Exclusive Distribution Agreement Concluded With This Works. GOODMINDTM Available For Sale In The United Kingdom And Europe - Exclusive Distribution Agreement Concluded With This Works. Toronto, Canada/ November, 29 2021 / Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the us...